Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

ScinoPharm Taiwan Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

22 Aug 2015 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - ScinoPharm Taiwan Ltd (1789-TW)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

28 Aug 2015 Thomson Reuters Stock Report 11 $25.00

Wright Investors Service Comprehensive Report for Scinopharm Taiwan Limited

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

26 Aug 2015 Wright Reports 55 $75.00

Scinopharm Taiwan Limited (1789) - Financial Analysis Review

Scinopharm Taiwan Limited (1789) - Financial Analysis Review Summary ScinoPharm Taiwan, Ltd. (ScinoPharm) is a pharmace...

21 Aug 2015 GlobalData 33 $125.00

Is Scinopharm Taiwan Limited Worth a Higher Bid?

20 Aug 2015 Sadif Analytics Prime 12 $25.00

神隆 (1789):向下游整合,然短期尚無法見到成效

神隆2015年成長動能來自學名藥,學名藥營收佔比將從76%增加到87%,而1H15減肥藥、抗憂鬱藥都沒出貨,元富預估神隆2015年營收41億元,YOY +0.35%;而神隆2015年毛利率將逐季回升,因先前缺貨大漲的抗癌藥原料紅豆杉供給已趨穩定,使神...

12 Aug 2015 MasterLink Securities Corporation 5 $35.00

神隆(1789.TT)營運持續轉型,惟評價仍高,維持中立

營運持續轉型,惟評價仍高,維持中立:研調處在神隆法說後,維持中立建議,主因(1)營運持續轉型,惟多數合作案預計要2017年後始可見效;(2)目前本益比近30倍,評價不低,維持中立建議。

06 Aug 2015 SinoPac Sec Investment Service Traditional Chinese 5 $35.00

Is Scinopharm Taiwan Limited Stock Still Attractive?

21 May 2015 Sadif Analytics Prime 12 $25.00

Scinopharm Taiwan Limited (1789) - Financial Analysis Review

Scinopharm Taiwan Limited (1789) - Financial Analysis Review Summary ScinoPharm Taiwan, Ltd. (ScinoPharm) is a pharmaceutical...

14 May 2015 GlobalData 33 $125.00

神隆(1789.TT)2015年營運復甦力道仍緩,維持中立

2015年營運復甦力道仍緩,維持中立:研調處在神隆法說後,維持中立建議,主因(1)雖癌症藥品端持續有新產品上市,但因主要產品面臨價格滑落壓力,致使整體成長動能受抑;(2)新藥客戶銷售不佳,公司閒置之產線短期不易調整;(3)針劑製劑藥品開發部分,要商業...

12 May 2015 SinoPac Sec Investment Service Traditional Chinese 4 $23.00